Richard Francis is President and Chief Executive Officer of Teva Pharmaceutical Industries Ltd (TEVA). The company reported total compensation of $19,168,709 for fiscal year 2025.
| Salary | $1,700,000 |
|---|---|
| Bonus | $0 |
| Stock awards | $11,999,970 |
| Option awards | $0 |
| Non-equity incentive plan | $4,827,405 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $641,334 |
| Total | $19,168,709 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Teva Pharmaceutical Industries Ltd filed March 31, 2026, accession 0001193125-26-134756.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | President and Chief Executive Officer | $1,700,000 | $0 | $11,999,970 | $0 | $4,827,405 | $0 | $641,334 | $19,168,709 |
| FY2024 | President and Chief Executive Officer | $1,600,000 | $1,500,000 | $8,999,988 | $0 | $2,885,100 | $0 | $533,859 | $15,518,947 |
| FY2023 | President and Chief Executive Officer | $1,600,000 | $1,500,000 | $18,999,993 | $0 | $2,600,000 | $0 | $1,006,887 | $25,706,880 |
Totals as disclosed in each year's own compensation disclosure for Teva Pharmaceutical Industries Ltd.
| Peer-group chief executive median | $26,480,462 |
|---|---|
| Difference from that median | $-7,311,753 |
| Percentile within the disclosed peer group | 1st |
| Peers with a disclosed figure | 1 |
Medians and percentiles are computed across the peer group Teva Pharmaceutical Industries Ltd discloses in its own compensation disclosure.
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Richard Francis this page | President and Chief Executive Officer | $19,168,709 |
| Evan Lippman | Executive Vice President, Business Development | $7,222,009 |
| Eli Kalif | Executive Vice President, Chief Financial Officer | $6,961,991 |
| Eric Hughes | Executive Vice President, Global R&D and Chief Medical Officer | $6,298,933 |
| Christine Fox | Executive Vice President, U.S. Commercial | $5,895,161 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Teva Pharmaceutical Industries Ltd compensation brief.
Richard Francis's compensation sits inside Teva Pharmaceutical Industries Ltd's full executive and board picture — the peer group, pay against peers, incentive design and the board itself.
The Teva Pharmaceutical Industries Ltd (TEVA) compensation brief